Bellerophon Therapeutics (NASDAQ: BLPH) 59.7% LOWER; announced top-line results from its PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix (BCM) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Brean Capital Reiterates Buy on GrubHub (GRUB) Following 2Q15 July 29, 2015 6:42 AM Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics July 28, 2015 9:23 AM Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale July 28, 2015 9:13 AM Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement July 28, 2015 8:19 AM Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO July 28, 2015 8:12 AM